The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Oct. 25, 11:36 PM

Slide #23. Portola Pharmaceuticals, Inc. Secondary Offering

Company: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)
Date announced: 10/1/2014
Shares Offered: 6,200,000
Date of Pricing: 10/2/2014
Price Per Share: $26.00
Secondary Offering Details: Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $160,000,000. All of the shares of common stock in the offering will be sold by Portola Pharmaceuticals. Subject to market and other conditions, the offering is expected to price before 9:30 a.m., EDT, on October 3, 2014. - updated 10/3 - Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today the pricing of its underwritten public offering of 6,200,000 shares of its common stock at a price to the public of $26.00 per share. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 930,000 shares from Portola at the public offering price. The offering is expected to close on October 8, 2014, subject to customary closing conditions.

Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. Co.'s product candidates in development include: Betrixaban, a novel oral once-daily inhibitor of Factor Xa in Phase 3 development for extended duration prophylaxis of a form of thrombosis; Andexanet alfa, a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor; Cerdulatinib, an orally available kinase inhibitor being developed for hematologic; and PRT2607 which is being developed in partnership with Biogen Idec Inc.
Open the PTLA Page at The Online Investor »

Company Name:  Portola Pharmaceuticals, Inc.
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding PTLA:  18
Total Market Value Held by ETFs:  $47.35M
Total Market Capitalization:  $1.10B
% of Market Cap. Held by ETFs:  4.32%

Open the PTLA Page at The Online Investor (in a new window) »

October 25, 2014    11:36 PM Eastern
Quotes delayed 20 minutes

Strong Buy (3.75 out of 4)
81st percentile
(ranked higher than approx. 81% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.